+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Beta-thalassemia (B-thal) Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2027-2032)

  • PDF Icon

    Report

  • 180 Pages
  • November 2026
  • Region: Global
  • Mordor Intelligence
  • ID: 6294670
The beta-thalassemia (B-thal) treatment market size is projected to be USD 6.01 billion in 2026, USD 6.41 billion in 2027, and reach USD 9.47 billion by 2032, growing at a CAGR of 8.12% from 2027 to 2032. This report is Segmented by Treatment Type (Iron Chelation Therapy, Erythroid Maturation Agents, and More), Disease Type (Beta-Thalassemia Major, Beta-Thalassemia Intermedia, Beta-Thalassemia Minor), End-User (Hospitals, Specialty Clinics, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). Market Forecasts are Provided in Terms of Value (USD).

Global Beta-thalassemia (B-thal) Treatment Market Trends and Insights

Rising Diagnosis and Screening in High-Prevalence Populations

The beta-thalassemia (B-thal) treatment market can expand as sequencing and screening programs identify patients whose needs were previously missed. An NGS-based newborn screening method in a Thai population correctly identified beta-thalassemia mutations in 95% of tested neonates and detected rare clinically significant variants missed by conventional multiplex PCR. A family-trio study covering 1,516 newborns in Guangxi found an 11.08% difference between parental screening predictions and neonatal results. This result shows why screening based on limited family information can leave clinically important cases unresolved. A study in Pakistan also found dual mutations in 11 of 64 carriers, supporting more complete genetic testing in consanguineous populations. As testing becomes more complete, the beta-thalassemia (B-thal) treatment market can gain formally diagnosed patients across chronic treatment, monitoring, and curative care.

Expansion of Curative Gene and Gene-Editing Therapies

The beta-thalassemia (B-thal) treatment market is moving beyond chronic disease control as gene-based treatments become available in more care settings. The U.S. Food and Drug Administration approved Casgevy for transfusion-dependent beta-thalassemia in January 2024. The European Commission approved Casgevy in February 2024, making a CRISPR/Cas9 gene-edited option available for eligible patients with transfusion-dependent beta-thalassemia. Italy began national reimbursement for Casgevy on October 8, 2025, and Policlinico San Matteo di Pavia administered the treatment outside a clinical trial in May 2025. The BTHAL-FT007-01 Phase IIb study began in July 2026 with an optimized lentiviral protocol, showing that gene addition continues alongside editing approaches.

Extreme Upfront Cost of Gene and Gene-Editing Therapies

The cost of genetic treatment remains a significant limit on the beta-thalassemia (B-thal) treatment market. A national reimbursement decision in Italy covered Casgevy for an eligible population of 5,000 patients under a monitored access framework. The economic challenge is substantial because one-time therapies require payment before their long-term benefit is fully observed. Outcomes-based contracts can reduce payer risk, but they require durable patient tracking and workable arrangements when patients change insurers. The CMS Cell and Gene Therapy Access Model began in January 2025 for sickle cell therapies, rather than transfusion-dependent beta-thalassemia. In lower-income endemic settings, chronic transfusion and chelation costs follow a different budget model, which makes the near-term adoption of high-cost one-time treatment more difficult.

Other drivers and restraints analyzed in the detailed report include:

  1. Increasing Adoption of Erythroid Maturation Agents
  2. Greater Use of Oral Iron Chelation and Home-Based Care
  3. Limited Authorized Treatment-Center Capacity

Segment Analysis

Iron chelation therapy held 38.32% of the beta-thalassemia (B-thal) treatment market share in 2026 because patients across disease severity levels require management of transfusional iron overload. Deferasirox remains central to this use because oral, once-daily treatment is easier to integrate into long-term care. A pediatric trial reported a mean serum ferritin reduction of 842 ng/mL with oral deferasirox, compared with 625 ng/mL with subcutaneous deferoxamine. The same evidence supports oral treatment where adherence is a practical part of clinical effectiveness. Stem cell transplant and gene therapy serve different clinical settings because transplant depends on an HLA-matched donor, and genetic therapies depend on specialized delivery capacity.

Erythroid maturation agents represent the fastest-growing treatment category, with the beta-thalassemia (B-thal) treatment market for this segment projected to increase at a CAGR of 9.22% through 2032. Luspatercept has long-term evidence showing sustained response and a reduction in liver iron when used with chelation. Its established clinical record gives prescribers evidence for chronic use in transfusion-dependent disease. Oral treatment may fit more readily into outpatient pathways than a subcutaneous injection given every 21 days. Chelators and erythroid maturation agents can be used together because a lower transfusion burden does not remove the need to manage accumulated iron.

Complete Report Scope:

  • By Treatment Type
    • Iron Chelation Therapy
    • Erythroid Maturation Agents
    • Stem Cell Therapy
    • Gene Therapy
    • Other Treatment Types
  • By Disease Type
    • Beta-thalassemia Major
    • Beta-thalassemia Intermedia
    • Beta-thalassemia Minor
  • By End-User
    • Hospitals
    • Specialty Clinics
    • Academic & Research Institutes
    • Home-care settings
    • Other End-Users
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • South America
      • Brazil
      • Argentina
      • Rest of South America

Geography Analysis

North America held a 48.22% share in 2026, supported by approved therapies and established payer systems. The region includes Casgevy, Zynteglo, and Reblozyl among the available treatment options. The CMS access model enrolled 33 states and the District of Columbia from January 2025, although its initial scope was sickle cell therapies. The model provides a useful payment framework for future transfusion-dependent beta-thalassemia discussions. Canada had 17 eligible treatment centers in a 2025 assessment, but bed and personnel availability could limit treatment volumes.

Europe is the second-largest geography, with demand linked to Mediterranean-heritage populations in Italy, Greece, Cyprus, Spain, France, and the United Kingdom. Italy’s reimbursement decision for Casgevy became effective in October 2025 and covered a nationally eligible group of 5,000 patients under registry monitoring. The region also gained a new oral treatment option when mitapivat received authorization for eligible adults with transfusion-dependent and non-transfusion-dependent thalassemia in 2026. France, Germany, the United Kingdom, and Spain retain national treatment networks that support specialized care. Austria’s St. Anna Kinderspital announced that it would begin administering Casgevy in late 2026.

Asia-Pacific is forecasted to record the highest growth rate, with the beta-thalassemia (B-thal) treatment market projected to advance at a CAGR of 10.35% through 2032. China carries more than 30 million thalassemia gene carriers, including 300,000 people with severe or intermediate disease. India faces limited donor availability and limited access to gene therapy, while a new 10-bed BMT center in Bengaluru indicates early capacity development. The Middle East and Africa demand is supported by GCC investment in specialized care, including Burjeel’s Abu Dhabi center. South America continues to rely mainly on transfusion and chelation, with gene therapy access dependent on future affordability pathways.



List of Companies Covered in this Report:

  1. Agios Pharmaceuticals, Inc.
  2. Beam Therapeutics Inc.
  3. Bluebird Bio
  4. Bristol-Myers Squibb
  5. Chiesi Farmaceutici
  6. Cipla
  7. CRISPR Therapeutics AG
  8. Disc Medicine, Inc.
  9. EdiGene Inc.
  10. Editas Medicine, Inc.
  11. Roche
  12. Merck
  13. Novartis
  14. Novo Nordisk
  15. Orchard Therapeutics plc
  16. Pfizer
  17. Sanofi
  18. Silence Therapeutics plc
  19. Vertex Pharmaceuticals
  20. Zydus Lifesciences Limited

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 Introduction
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 Research Methodology3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Diagnosis and Screening in High-Prevalence Populations
4.2.2 Expansion of Curative Gene and Gene-Editing Therapies
4.2.3 Increasing Adoption of Erythroid Maturation Agents
4.2.4 Greater Use of Oral Iron Chelation and Home-Based Care
4.2.5 Growth of Specialized Hemoglobinopathy Treatment Centers
4.2.6 Outcome-Based Reimbursement for One-Time Therapies
4.3 Market Restraints
4.3.1 Extreme Upfront Cost of Gene and Gene-Editing Therapies
4.3.2 Limited Authorized Treatment-Center Capacity
4.3.3 Inconsistent Diagnosis and Patient Registries in Endemic Countries
4.3.4 Long-Term Safety and Durability Uncertainty for Genetic Therapies
4.4 Supply Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Threat of New Entrants
4.7.2 Bargaining Power of Suppliers
4.7.3 Bargaining Power of Buyers
4.7.4 Threat of Substitutes
4.7.5 Competitive Rivalry
5 Market Size & Growth Forecasts (Value, USD)
5.1 By Treatment Type
5.1.1 Iron Chelation Therapy
5.1.2 Erythroid Maturation Agents
5.1.3 Stem Cell Therapy
5.1.4 Gene Therapy
5.1.5 Other Treatment Types
5.2 By Disease Type
5.2.1 Beta-thalassemia Major
5.2.2 Beta-thalassemia Intermedia
5.2.3 Beta-thalassemia Minor
5.3 By End-User
5.3.1 Hospitals
5.3.2 Specialty Clinics
5.3.3 Academic & Research Institutes
5.3.4 Home-care settings
5.3.5 Other End-Users
5.4 By Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, Recent Developments)
6.3.1 Agios Pharmaceuticals, Inc.
6.3.2 Beam Therapeutics Inc.
6.3.3 bluebird bio, Inc.
6.3.4 Bristol Myers Squibb
6.3.5 Chiesi Farmaceutici S.p.A.
6.3.6 Cipla Limited
6.3.7 CRISPR Therapeutics AG
6.3.8 Disc Medicine, Inc.
6.3.9 EdiGene Inc.
6.3.10 Editas Medicine, Inc.
6.3.11 F. Hoffmann-La Roche Ltd
6.3.12 Merck KGaA
6.3.13 Novartis AG
6.3.14 Novo Nordisk A/S
6.3.15 Orchard Therapeutics plc
6.3.16 Pfizer Inc.
6.3.17 Sanofi
6.3.18 Silence Therapeutics plc
6.3.19 Vertex Pharmaceuticals Incorporated
6.3.20 Zydus Lifesciences Limited
7 Market Opportunities & Future Outlook
7.1 White-space & Unmet-need Assessment

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Agios Pharmaceuticals, Inc.
  • Beam Therapeutics Inc.
  • bluebird bio, Inc.
  • Bristol Myers Squibb
  • Chiesi Farmaceutici S.p.A.
  • Cipla Limited
  • CRISPR Therapeutics AG
  • Disc Medicine, Inc.
  • EdiGene Inc.
  • Editas Medicine, Inc.
  • F. Hoffmann-La Roche Ltd
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk A/S
  • Orchard Therapeutics plc
  • Pfizer Inc.
  • Sanofi
  • Silence Therapeutics plc
  • Vertex Pharmaceuticals Incorporated
  • Zydus Lifesciences Limited